Los Angeles, CA – In a significant stride against one of the most aggressive and challenging forms of cancer, researchers at Keck Medicine of USC have unveiled a promising new combination therapy for glioblastoma, a devastating brain tumor historically associated with a grim prognosis. A recent study, spearheaded by Keck Medicine of USC neuro-oncologists, suggests that integrating Tumor Treating Fields (TTFields) therapy with immunotherapy and chemotherapy could dramatically extend the survival of patients, particularly those with larger, inoperable tumors, offering a beacon of hope where few effective treatments currently exist.
According to the National Brain Tumor Society, the average survival for patients diagnosed with glioblastoma stands at a sobering eight months. This new research, however, provides compelling evidence that a multi-modal approach can significantly alter this bleak outlook, potentially revolutionizing the treatment paradigm for this formidable disease.
The Unyielding Challenge of Glioblastoma
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults. Its notorious resistance to conventional therapies stems from several inherent biological complexities. These tumors are highly infiltrative, making complete surgical resection often impossible, and they are characterized by rapid, uncontrolled growth. Furthermore, the brain’s unique environment, shielded by the blood-brain barrier, poses a formidable obstacle to drug delivery, while an inherently immunosuppressive tumor microenvironment actively repels the body’s natural defenses.
For decades, the standard of care has involved a combination of surgery (when feasible), radiation therapy, and chemotherapy with temozolomide (TMZ). While these treatments can temporarily slow progression, they rarely offer long-term remission, and recurrence is almost inevitable. Immunotherapy, which has proven transformative for many other cancer types by harnessing the body’s immune system, has largely faltered when applied to glioblastoma as a standalone treatment, primarily due to the tumor’s ability to evade immune recognition and response. The urgent need for innovative and more effective therapeutic strategies has been a driving force in neuro-oncology research worldwide.
A Novel Synergy: Unpacking the Combination Therapy
The Keck Medicine of USC study, published in a leading oncology journal, pinpoints a synergistic effect achieved by combining three distinct therapeutic modalities: Tumor Treating Fields (TTFields), the immune checkpoint inhibitor pembrolizumab, and the chemotherapy agent temozolomide.
Understanding Tumor Treating Fields (TTFields):
TTFields therapy, delivered via a medical device, represents a unique approach to cancer treatment. It employs low-intensity, alternating electric fields that are precisely targeted to the tumor site. These electric fields exert mechanical forces on key cellular components during cell division (mitosis), physically disrupting the formation of the mitotic spindle and preventing cancer cells from multiplying. Approved by the FDA for glioblastoma, TTFields are delivered non-invasively through a set of mesh electrodes strategically positioned on the patient’s scalp. Patients typically wear these electrodes for approximately 18 hours a day, generating fields at a precise frequency and intensity designed to focus on the tumor while sparing healthy brain tissue.
Beyond its direct anti-proliferative effects, the study highlights a crucial secondary mechanism of TTFields: its ability to signal the body’s immune system. Researchers observed that TTFields attract more tumor-fighting T cells—a type of white blood cell essential for identifying and attacking cancer cells—into and around the glioblastoma. This influx of immune cells is a critical first step in overcoming the tumor’s natural immunosuppressive defenses.
The Immunotherapy Component: Pembrolizumab:
Pembrolizumab is an immune checkpoint inhibitor (ICI) that works by blocking the PD-1 protein on T cells. By blocking PD-1, pembrolizumab essentially "removes the brakes" from the immune system, allowing T cells to remain active longer and more effectively recognize and attack cancer cells. While remarkably successful in cancers like melanoma and lung cancer, ICIs have struggled against glioblastoma due to the scarcity of T cells within the tumor’s microenvironment, a consequence of the blood-brain barrier and the tumor’s inherent immune evasion strategies.
Chemotherapy’s Role: Temozolomide:
Temozolomide (TMZ) is an oral chemotherapy drug that damages DNA in cancer cells, inhibiting their growth. It has been a cornerstone of glioblastoma treatment for years, typically administered after surgery and radiation. While effective in some patients, its overall impact on long-term survival for glioblastoma remains modest when used alone or in combination with radiation.
The Mechanism of Action: Priming the Immune System for Attack
The groundbreaking aspect of this research lies in understanding how these therapies interact to produce such a significant outcome. Dr. David Tran, MD, PhD, chief of neuro-oncology with Keck Medicine, co-director of the USC Brain Tumor Center, and corresponding author of the study, theorized that the key to unlocking immunotherapy’s potential in glioblastoma was to initiate an immune reaction directly within the tumor itself—an approach known as "in situ immunization."
"By using TTFields with immunotherapy, we prime the body to mount an attack on the cancer, which enables the immunotherapy to have a meaningful effect in ways that it could not before," explained Dr. Tran. "Our findings suggest that TTFields may be the key to unlocking the value of immunotherapy in treating glioblastoma."
The study elucidates this intricate dance:
- TTFields as the "Immune Attractor": The electric fields generated by TTFields therapy disrupt tumor cells, potentially leading to the release of tumor antigens (molecules that can be recognized by the immune system) and the activation of danger signals. Crucially, TTFields also appear to facilitate the migration of tumor-fighting T cells into the glioblastoma microenvironment, overcoming the natural barrier that often keeps these immune cells out.
- TTFields as the "Tumor Weakener": Beyond attracting immune cells, TTFields directly compromise the tumor’s structural integrity and ability to proliferate, making the cancer cells more vulnerable to attack.
- Immunotherapy as the "Amplifier": Once TTFields have drawn T cells into the tumor and weakened its defenses, pembrolizumab steps in. By inhibiting PD-1, it prevents these newly recruited T cells from becoming exhausted or deactivated by the tumor’s immunosuppressive mechanisms. This allows the T cells to stay active longer and proliferate, leading to a sustained and potent immune response against the cancer.
Dr. Tran articulates this synergy using a compelling analogy: "Think of it like a team sport – immunotherapy sends players in to attack the tumor (the offense), while TTFields weaken the tumor’s ability to fight back (the defense). And just like in team sports, the best defense is a good offense." This "one-two punch" effectively bypasses the tumor’s inherent resistance to immunotherapy by first creating an immune-permissive environment, then unleashing the full power of the immune system.
The 2-THE-TOP Phase 2 Trial: Evidence of Hope
The foundational data for this breakthrough comes from the 2-THE-TOP, a Phase 2 clinical trial that rigorously evaluated this multi-modal treatment strategy.
Study Methodology and Patient Cohort:
The trial enrolled 31 newly diagnosed glioblastoma patients who had already completed standard chemoradiation therapy. Of this cohort, 26 patients received the full triple-combination therapy: TTFields, chemotherapy (temozolomide), and immunotherapy (pembrolizumab). A particularly significant subgroup within this trial consisted of seven patients who had inoperable tumors due to their challenging locations. This subgroup typically faces the worst prognosis and has historically had the fewest treatment options, making any positive outcome especially noteworthy.
Patients in the trial received six to twelve monthly treatments of chemotherapy alongside TTFields for up to 24 months, with the duration tailored to their individual response. The immunotherapy, pembrolizumab, was administered every three weeks, commencing with the second dose of chemotherapy, also for up to 24 months. This structured regimen allowed researchers to closely monitor the efficacy and safety of the combined approach.
Remarkable Results:
The findings from the 2-THE-TOP trial were nothing short of remarkable, offering unprecedented hope for glioblastoma patients:
- Significant Overall Survival Increase: Patients who received the triple therapy (TTFields, chemotherapy, and immunotherapy) lived approximately 10 months longer than historical controls who had previously used TTFields with chemotherapy alone. This represents a substantial improvement in a disease where months are precious.
- 70% Increase in Overall Survival: Compared to historical benchmarks for similar patient populations, the combination therapy was associated with a 70% increase in overall survival, a statistically and clinically significant finding.
- Exceptional Outcomes for High-Risk Patients: Perhaps most compelling were the results for patients with large, inoperable (unresected) tumors. This subgroup, typically facing the most dire prognosis, lived approximately 13 months longer than patients who underwent surgical removal of their tumors. Moreover, these patients showed a much stronger immune activation, suggesting that having a larger tumor might paradoxically provide more targets for the therapy to work against, effectively "kick-starting" a more robust immune response.
"Further studies are needed to determine the optimal role of surgery in this setting, but these findings may offer hope, particularly for glioblastoma patients who do not have surgery as an option," Dr. Tran acknowledged, hinting at a potential paradigm shift where surgical removal might not always be the primary determinant of a patient’s prognosis.
Expert Perspectives and Future Directions
The success of the 2-THE-TOP Phase 2 trial has set the stage for the next crucial step in validating this promising therapy.
Validation in a Global Phase 3 Trial:
Keck Medicine of USC is actively participating in a multicenter, international Phase 3 clinical trial designed to definitively validate the efficacy and safety of TTFields combined with immunotherapy and chemotherapy. Dr. David Tran, a veteran researcher who has dedicated over a decade to studying TTFields, chairs the steering committee for this pivotal trial, underscoring the confidence and commitment behind this research. Dr. Frances Chow, MD, a neuro-oncologist with USC Norris Comprehensive Cancer Center, serves as the principal investigator for the Keck Medicine study site.
This expansive Phase 3 trial is currently open at 28 sites across the United States, Europe, and Israel. It aims to enroll over 740 patients by April 2029, encompassing a broad spectrum of glioblastoma patients, including those with gross total resection, partial resection, or biopsy-only tumors. This comprehensive approach will allow researchers to precisely assess how the extent of surgical tumor removal influences the immune response and overall treatment outcomes.
Implications for Patients and the Future of Neuro-Oncology:
The implications of this research are profound. For glioblastoma patients and their families, these findings offer a tangible sense of hope in a landscape often defined by limited options. The potential to extend survival by a significant margin, particularly for those with inoperable tumors, represents a monumental leap forward.
Beyond glioblastoma, this study’s insights into modulating the tumor microenvironment and leveraging in situ immunization could pave the way for similar combination therapies in other challenging brain cancers or even solid tumors known for their immunosuppressive properties. It underscores the growing understanding that effective cancer treatment often requires not just direct attack, but also the strategic enlistment and amplification of the body’s own immune system.
The journey from initial discovery to widespread clinical application is long and arduous, but the results from the Keck Medicine of USC study provide compelling evidence that neuro-oncology is on the cusp of a transformative era for glioblastoma treatment. The ongoing Phase 3 trial is poised to confirm these findings, potentially ushering in a new standard of care that offers not just extended life, but also renewed hope for patients facing this formidable diagnosis.
Keck School of Medicine of USC authors of this study include Dongjiang Chen, PhD, assistant professor of research neurological surgery; Son Le, PhD, assistant professor of research neurological surgery; Harshit Manektalia, research programmer; Ming Li, PhD, professor of research population and public health sciences; and Adam O’Dell, research lab specialist. Ashley Ghiaseddin, MD, and Maryam Rahman, MD, MS, colleagues from the University of Florida, also contributed to this work.
This study was funded by a grant from Novocure, which manufactures Optune, the TTFields device used in this study. Dr. David Tran has received honoraria from Novocure for consultant work. Dr. Dongjiang Chen and Dr. David Tran are inventors of two patent applications related to work reported in this study, reflecting their significant intellectual contribution to this innovative therapeutic approach.
About the Author
